Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Business Wire
ReSonance is Manufactured by a Proprietary Process, Developed In-House, at Clinical Scale, with Relevant In-Vitro Functional ActivityImmediate-Use, Thaw-and-Inject Formulation Durably Engrafted in Multiple Preclinical Hearing Loss ModelsReSonance is Currently Being Evaluated in a Functional Model of Hearing Loss CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that preclinical results with ReSonance (ANP1), the Company’s auditory neuronal cell transplant for the treatment of hearing loss, were presented at the 59th Annual Inner Ear Biology Workshop by Ofer Wiser, Ph.D. Senior Scientist, Technological Innovation at Cell Cure Neurosciences, Inc., the Company’s Israel-based subsidiary, which is responsible for research, process development, and good manufacturing practice (GMP) production.“We are excited to report on the
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct OfferingBusiness Wire
- Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct OfferingBusiness Wire